Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Up 53.6% in November

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 101,400 shares, an increase of 53.6% from the October 31st total of 66,000 shares. Based on an average daily volume of 139,700 shares, the short-interest ratio is currently 0.7 days. Approximately 0.4% of the company’s stock are sold short.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. acquired a new position in Bolt Biotherapeutics during the 2nd quarter worth $26,000. Acuitas Investments LLC lifted its position in shares of Bolt Biotherapeutics by 21.7% in the 2nd quarter. Acuitas Investments LLC now owns 630,507 shares of the company’s stock worth $473,000 after acquiring an additional 112,555 shares during the period. Finally, FMR LLC lifted its position in Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after purchasing an additional 28,773 shares during the period. Institutional investors own 86.70% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, November 13th. Five research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Price Performance

NASDAQ:BOLT traded up $0.02 during trading hours on Friday, reaching $0.64. The company’s stock had a trading volume of 132,236 shares, compared to its average volume of 111,789. Bolt Biotherapeutics has a one year low of $0.54 and a one year high of $1.56. The business’s 50-day moving average is $0.63 and its 200-day moving average is $0.69. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The company had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.02 million. Research analysts anticipate that Bolt Biotherapeutics will post -1.61 EPS for the current year.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.